Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 19, 2024 06:10 ET
|
Alvotech
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to...
Alvotech gerir sölusamning í Bandaríkjunum um fyrstu líftæknilyfjahliðstæðuna í háum styrk með útskiptanleika við Humira
April 19, 2024 06:10 ET
|
Alvotech
Langtímasamningur hefur náðst við leiðandi innkaupaaðila lyfja í Bandaríkjunum um sölu- og dreifingu á líftæknilyfjahliðstæðu Alvotech í háum styrk með útskiptanleika við HumiraMeð þessum samningi...
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 19, 2024 06:10 ET
|
Alvotech
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to...
Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Selarsdi (ustekinumab-aekn) líftæknilyfjahliðstæðu við Stelara
April 16, 2024 17:30 ET
|
Alvotech
Markaðsleyfið er fyrir notkun lyfsins til meðferðar bæði á fullorðnum og börnum Þetta er önnur líftæknilyfjahliðstæða Alvotech sem hlýtur markaðsleyfi í Bandaríkjunum Gert er ráð fyrir að Selarsdi...
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024 17:30 ET
|
Alvotech
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the...
Alvotech tilkynnir um útgáfu eigin hlutabréfa
March 22, 2024 16:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að stjórn fyrirtækisins hefði ákveðið að gefa út þrettán milljón (13.000.000) nýja almenna hluti í félaginu. Dótturfélag Alvotech, Alvotech Manco ehf....
Alvotech Announces Increase in Number of Own Shares
March 22, 2024 16:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share...
Alvotech birtir uppgjör fyrir árið 2023 og kynnir nýjustu áfanga í rekstri félagsins
March 20, 2024 16:15 ET
|
Alvotech
Heildartekjur á árinu 2023 voru 93,4 milljónir dollara, sem er 10% aukning frá fyrra áriSölutekjur á árinu 2023 voru 48,7 milljónir dollara, samanborið við 24,8 milljónir dollara á árinu 2022, og voru...
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
March 20, 2024 16:15 ET
|
Alvotech
Total Revenues in 2023 were $93.4 million, up 10% from previous yearProduct Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million, up...
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
March 20, 2024 16:15 ET
|
Alvotech
Total Revenues in 2023 were $93.4 million, up 10% from previous yearProduct Revenues in 2023 were $48.7 million, compared to $24.8 million in 2022, with Q4 2023 product revenues of $18.9 million, up...